PBF-680, an oral A1 adenosine receptor antagonist, increases trough forced expiratory volume in 1 second (FEV1) in mild-to-moderate asthma: a Phase-II trial - Vienna 2024

Novel treatment strategies for airway diseases: a glimpse into the future

Chair(s): Tania Maes, Juan Jos Nieto-Fontarigo

Session type: Poster session

PBF-680, an oral A1 adenosine receptor antagonist, increases trough forced expiratory volume in 1 second (FEV1) in mild-to-moderate asthma: a Phase-II trial

David Ramos Barbon

EVENTS HOME

Poster
Abstract

Previous presentation

Next presentation

Session content

Cutting-edge 3D COPD lung mimic

Eline Geervliet

Poster

Abstract

Biologic treatment specifically increases resting regulatory T-cells (Tregs) in blood of patients with severe asthma

Marek Lommatzsch

Poster

Abstract

A long-acting high affinity anti-TSLP antibody (GB-0895) for severe asthma identified leveraging a proprietary machine learning platform

Kapil Mayawala

Abstract

Differential effects of Ruxolitinib on airway remodeling in asthma and COPD

Maria Elpida Christopoulou

Poster

Abstract

Pharmacokinetics (PK) of the anti-ST2 monoclonal antibody, astegolimab

Wenhui Zhang

Poster

Abstract

APATURA: a Phase 2a study of elarekibep, an inhaled IL-4 receptor alpha inhibitor, in moderate-to-severe asthma

Tania Hugo

Poster

Abstract

Resolvin D1 reduces the inflammatory response to rhinovirus infection in COPD bronchial epithelial cells

Jordina Mah

Poster

Abstract

Shikonin alleviates asthmatic airway inflammation in mice through STAT3-dependent mechanism in airway epithelial cells

Haifeng Ouyang

Poster

Abstract

Characteristics of U-BIOPRED endotypes from multi-omics integration of 24 high-dimensional/throughput data

Nazanin Zounemat-kermani

Poster

Abstract

Efficacy and safety of CM310 in moderate to severe asthma: a multicenter, randomized, double-blind, placebo-controlled phase 2 study

Nan Su

Poster

Abstract

PBF-680, an oral A1 adenosine receptor antagonist, increases trough forced expiratory volume in 1 second (FEV1) in mild-to-moderate asthma: a Phase-II trial

David Ramos Barbon

Poster

Abstract

Efficacy and safety of Suhuang Zhike Capsules in the treatment of asthma: A multicenter, randomized, double-blinded, placebo-controlled trial

Yilin Pan

Poster

Abstract

Increased IL-4 receptor expression in COPD small airway remodelling

Andrew Higham

Abstract

The pathophysiological role of IL-13 in COPD

Andrew Higham

Abstract

Pharmacological characterization of the relaxant effect of RCD405 in isolated human medium bronchi

Paola Rogliani

Poster

Abstract

Endocannabinoids suppress inflammation-induced tumor necrosis factor alpha up-regulation in human and Guinea-pig lungs

Reshed Abohalaka

Poster

Abstract

Metabolomic analysis of the effect of endocannabinoid metabolism inhibition in allergic airway inflammation

Reshed Abohalaka

Poster

Abstract

Arg16Gly ?2-Adrenoreceptor Polymorphism in Severe Eosinophilic Asthma: Implications for Mepolizumab Long-Term Effectiveness and Clinical Remission

Santi Nolasco

Poster

Abstract

CDN Connection Issue

The ERS Congress 2024, Vienna

#{title}